{"id":971,"date":"2026-08-26T20:43:37","date_gmt":"2026-08-26T20:43:37","guid":{"rendered":"https:\/\/noimfine.com\/sph06\/?p=971"},"modified":"2026-09-26T20:49:13","modified_gmt":"2026-09-26T20:49:13","slug":"beqalzi-fda-approves-new-oral-bcl-2-blocker-for-relapsed-or-refractory-mantle-cell-lymphoma-2","status":"publish","type":"post","link":"https:\/\/noimfine.com\/sph06\/2026\/08\/26\/beqalzi-fda-approves-new-oral-bcl-2-blocker-for-relapsed-or-refractory-mantle-cell-lymphoma-2\/","title":{"rendered":"Beqalzi: FDA Approves New Oral BCL-2 Blocker for Relapsed or Refractory Mantle Cell Lymphoma"},"content":{"rendered":"<div><!--[--><!--&gt;--><\/p>\n<div>\n<div>\n<div>\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<div>\n<div>\n<section><a href=\"https:\/\/reference.medscape.com\/drug\/sonrotoclax-4000584#0\">Beqalzi<\/a> (sonrotoclax) is a prescription, targeted, oral cancer medicine that has received accelerated FDA approval for treating adults with mantle cell lymphoma (MCL) that has relapsed or become resistant after at least two prior treatments, including treatment with a Bruton\u2019s tyrosine kinase (BTK) inhibitor.<iframe src=\"https:\/\/www.youtube.com\/embed\/KZ-poa6dfmU\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>MCL is a rare and aggressive cancer that affects B cells, a type of white blood cell found in the lymph nodes.<iframe src=\"https:\/\/www.youtube.com\/embed\/jMTfKIg3B2A\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>It is considered a subtype of non-Hodgkin lymphoma that can quickly spread beyond the lymph nodes to other parts of the body, such as the bone marrow, spleen, liver, and digestive tract.<iframe src=\"https:\/\/www.youtube.com\/embed\/CKEyCSdmb-s\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>MCL is typically diagnosed in people in their 60s and at an advanced stage.<iframe src=\"https:\/\/www.youtube.com\/embed\/xt5emaghnY4\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>In the United States, about 3,300 people are diagnosed each year, with most cases occurring in men. Initial care often works, but relapse is common, and outcomes are usually poor, especially if the person has already received a BTK inhibitor. Beqalzi works by blocking a protein called B-cell lymphoma 2 (BCL-2), which many cancer cells overproduce to help them survive and resist chemotherapy. Normally, damaged or old cells are programmed to die through a process called apoptosis. Cancer cells evade apoptosis by using BCL-2 as a kind of \u201csurvival shield.\u201d By blocking BCL-2, Beqalzi removes the shield, allowing the body\u2019s natural signals to trigger cancer cell death. This approval matters because Beqalzi provides a new targeted treatment option for patients with MCL who have fewer choices after multiple prior therapies. This medicine was designed to selectively block cancer cell survival signals and promote apoptosis, with intended improvements in effectiveness, tolerability, and convenience compared with earlier therapies in the same class.<\/section>\n<section>\n<h2>Why Was It Approved?<\/h2>\n<p>The FDA\u2019s accelerated approval for Beqalzi was based on positive results from an early clinical study showing tumor shrinkage and the long duration of responses in patients with relapsed or treatment-resistant MCL. Continued approval depends on findings of real clinical benefit from confirmatory studies. The single-arm clinical study was carried out in 103 adults with relapsed or refractory MCL who had received anti-CD20 therapy and a BTK inhibitor. The results showed that about 52% of patients saw their cancer shrink, with about 16% of patients showing no detectable signs of cancer after treatment. Patients typically responded in about 1.9 months, and the almost year-long follow-up study showed that the benefit lasted a median of 15.8 months (at the time of analysis). The treatment was generally well tolerated.<\/section>\n<\/div>\n<div>\n<section>The most common side effects are pneumonia and fatigue. The most common serious lab abnormalities are low counts of lymphocytes and neutrophils, which are types of white blood cells that help fight infection. Thus, Beqalzi can cause fatal or serious infections. One of the most important warnings is an increased risk for tumor lysis syndrome (TLS), a serious or life-threatening condition that can occur when cancer cells break down quickly and release their contents into the blood.<\/section>\n<section>\n<h2>What Do I Need to Know?<\/h2>\n<p>You may have to take Beqalzi in a hospital or medical office setting to allow monitoring for TLS. Your health care provider will start your therapy with a four-week dose ramp-up to reduce the risk for TLS. After that, you will take 320 milligrams once daily until your disease worsens or side effects require a change. Take Beqalzi orally with a meal at about the same time each day. Swallow the tablets whole with water. Do not break, chew, or crush them. If you miss a dose and eight hours haven\u2019t passed, take it right away with food and go back to your normal schedule the next day. If more than eight hours have passed, skip it and take the next dose at the usual time. If you vomit after a dose, do not take another dose that day. Before starting Beqalzi, your health care provider will check your risk for TLS and initiate prevention steps such as extra fluids and medicines to lower uric acid levels. During the treatment, your health care provider will frequently monitor your blood work. This is especially important when starting the medicine, increasing the dose, or restarting treatment. Some patients who are at a higher risk for TLS may need hospital monitoring with intravenous fluids. Your health care provider may also advise you to stay well hydrated during the treatment to reduce your risk of TLS. They will also check your neutrophil counts regularly during the treatment. Inform your health care provider about all medicines, vitamins, and supplements that you take to avoid possible interactions. Avoid certain medicines such as strong or moderate CYP3A inhibitors and CYP3A inducers as they can affect Beqalzi\u2019s breakdown (metabolism) in your body, affecting its safety or effectiveness.<\/section>\n<\/div>\n<div>\n<section>Also avoid consuming grapefruit, Seville oranges, and star fruit or products containing any of them while receiving Beqalzi. Beqalzi can harm a fetus. Your health care provider may check your pregnancy status before you start treatment. Use birth control during treatment and for one week after the last dose. Men with partners who can become pregnant should also use birth control. Do not breastfeed during treatment and for one week after the last dose. Call your health care provider right away if you get a fever or notice any signs of an infection or if you experience nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, decreased urination, muscle cramps\/twitches. These may be signs of serious side effects.<\/section>\n<\/div>\n<\/div>\n<p><!--&gt;<\/div>\n\n\n--><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beqalzi (sonrotoclax) is a prescription, targeted, oral cancer medicine that has received accelerated FDA approval for treating adults with mantle cell lymphoma (MCL) that has relapsed or become resistant after at least two prior treatments, including treatment with a Bruton\u2019s&#8230; <\/p>\n","protected":false},"author":2,"featured_media":328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/comments?post=971"}],"version-history":[{"count":1,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/971\/revisions"}],"predecessor-version":[{"id":979,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/971\/revisions\/979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media\/328"}],"wp:attachment":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media?parent=971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/categories?post=971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/tags?post=971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}